The FDA Black Box Warning Does Reduce the Use of Erythropoietin Stimulating Agents and Increases Blood Transfusions in Insured, Low Income Cancer Patients.
The FDA Black Box Warning Does Reduce the Use of Erythropoietin Stimulating Agents and Increases Blood Transfusions in Insured, Low Income Cancer Patients. Value Health. 2014 Nov; 17(7):A655.